Chemicals
Bayer’s Two-Front Offensive: Legal Closure Paves the Way for a Pipeline-Fueled Rebound
The Supreme Court’s 7–2 ruling excising thousands of Roundup claims from Bayer’s docket was the kind of event that sends...
Mutares Heads Into Late-June Gauntlet With a No-Cash Deal and a Dividend Question
The coming week will test whether Mutares can simultaneously clear a covenant hurdle, integrate a loss-making Czech chemicals plant, and...
BASF Completes Initial Buyback Phase as €12 Billion Capital Return Program Gathers Pace
The first chapter of BASF’s ambitious shareholder payout story is closing. By the end of June, the chemicals giant will...
Judgment Day for Bayer: Supreme Court Ruling Looms Over New CFO and Pipeline Progress
Bayer shares vaulted 4.6% to €37.51 on Thursday, hitting a monthly high as investors placed their bets on a single...
Germany Adds Pesticide-Triggered Parkinson’s to Occupational Disease List, as Only 30% of Claims Win Approval
The path to compensation for occupational illnesses in Germany remains a steep climb. Of the 90,749 suspected cases reported last...
Bayer’s Technical Battle at the 200-Day Line Gets Reinforcement from Agriculture AI and Kidney Drug Progress
Bayer shares entered the week walking a tightrope just above a key long-term trendline, but the company’s pipeline and digital...
Bayer’s Summer of Reckoning: Legal Decisions and a Potential Blockbuster Collide
Bayer’s stock is caught in a familiar squeeze: strong operational performance and promising drug data are consistently overshadowed by the...
Bayer’s Fundamentals Swing Upward, but the 200-Day Line Remains a Battleground
Bayer delivered a first-quarter earnings report that should have been a catalyst for its stock. Adjusted earnings per share jumped...
BASF’s Circular Supply Chain Pivot and Coatings Divestiture Set Stage for Share Buyback Surge
The chemical giant is quietly assembling the pieces for a transformation on two fronts. While deepening its foothold in chemical...
Bayer’s €7 Billion Insurance Policy: Shareholders Back a Capital Cushion for the Glyphosate Endgame
Bayer’s annual general meeting on April 24 was a study in contradictions. Major institutional investors praised CEO Bill Anderson’s restructuring...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
